Transcatheter Aortic Valve Implantation (TAVI) Market Growing at a Highest CAGR of 14.2%, Leading Players are Abbott Laboratories, Boston Scientific Corporation, Blue Sail Medical Co. Ltd., Bracco

Delvens published an exclusive report, titled, "Transcatheter Aortic Valve Implantation (TAVI) Market Growing at a Highest CAGR of 14.2%, Leading Players are Abbott Laboratories, Boston Scientific Corporation, Blue Sail Medical Co. Ltd., Bracco". The Transcatheter Aortic Valve Implantation (TAVI) Market research report Provides comprehensive information on the market offered by the key players. It offers details of market development and provides in-depth information about lucrative emerging markets, and analyzes penetration across mature market segments. The Transcatheter Aortic Valve Implantation (TAVI) Market research report provides detailed information about new product launches, untapped geographies, recent developments, and investments.

Click Here For Free Sample + Related Graphs of the Report at: https://www.delvens.com/get-free-sample/transcatheter-aortic-valve-implantation-market-trends-forecast-till-2028

Transcatheter Aortic Valve Implantation (TAVI) Market Key Players:

Abbott Laboratories
Boston Scientific Corporation
Blue Sail Medical Co. Ltd.
Bracco
Edward Lifesciences
JC Medical Inc.
JenaValve Techologies Inc.
Medtronic Plc
Meril Lifesciences
Venus Medtech

Developments in Recent Times

The US Food and Drug Administration (FDA) granted Edwards Lifesciences certification for their SAPIEN 3 Ultra system in March 2021 for the treatment of severe, symptomatic aortic stenosis in low-risk patients. The SAPIEN 3 Ultra system is a TAVI device of the latest generation that provides better delivery and placement.

The introduction of Medtronic's Evolut FX TAVI system in Europe was scheduled for February 2021. The Evolut FX TAVI system includes cutting-edge features including a completely retrievable and repositionable valve in order to speed and simplify the TAVI operation.

Boston Scientific stated in January 2021 that it had successfully acquired Preventice Solutions, a company that offers cardiac patients remote monitoring and diagnostic tools. Boston Scientific's digital health capabilities are anticipated to be strengthened by the purchase, allowing the business to provide patients undergoing TAVI operations with more complete solutions.

The FDA gave Abbott Laboratories' Tendyne Transcatheter Mitral Valve Implantation (TMVI) device, which is intended to treat severe mitral regurgitation, approval in October 2020. For patients with mitral valve dysfunction, the Tendyne TMVI system, a first-of-its-kind device, provides a minimally invasive alternative to open heart surgery.

Market Analysis and Growth Depending on Segmentations

Valve Type

The market for TAVI is anticipated to be dominated by the segment of transfemoral valves because of their greater acceptance rate and simpler accessibility for medical professionals. Transapical and transaortic valves, however, are also anticipated to expand because to the advantages they provide for some patient groups, such as those with smaller arteries or more complicated anatomy.

End-User

Due to the high amount of TAVI treatments carried out in these settings, hospitals are the main end-users of TAVI devices and are predicted to maintain their market dominance. However, because of its reduced cost and quicker recovery periods, TAVI treatments are becoming more popular in ambulatory surgery centers (ASCs).

Geography

Due to the widespread occurrence of aortic stenosis and favorable reimbursement rules, North America now has the largest regional market for TAVI devices. Due to an aging population and a high incidence of aortic stenosis, Europe is a sizable market for TAVI devices. A considerable growth rate is anticipated for the Asia-Pacific area as a result of rising demand for minimally invasive treatments and expanding healthcare facilities.

The development of new and improved TAVI devices, greater public knowledge of the advantages of minimally invasive treatments, and an increase in the number of TAVI operations being performed globally are all factors boosting the market for TAVI. The market is also expanding as a result of numerous nations' favorable reimbursement policies for TAVI operations.

Key Drivers in the Market

Growing Prevalence of Aortic Stenosis
A frequent condition of the heart valves called aortic stenosis is mostly seen in elderly people. Aortic stenosis is becoming more common as the population ages, which is increasing the need for TAVI surgeries.

Advancements in TAVI Technology

The creation of updated TAVI devices has made it possible for medical professionals to carry out minimally invasive treatments more precisely and accurately. As a result, more people are choosing TAVI operations as an effective substitute for open-heart surgery.

Favorable Reimbursement Policies

The market is expanding as a result of the favorable reimbursement policies that have been enacted in several nations for TAVI operations.

Rising Demand for Minimally Invasive Procedures
Minimally invasive treatments that provide quicker recovery periods and decreased risk of problems are becoming more popular with patients. These requirements are met by TAVI treatments, which are in great demand.

Increasing Awareness about the Benefits of TAVI
The demand for TAVI operations is anticipated to increase as more patients and doctors become aware of their advantages.

Due to these important factors, the TAVI market is anticipated to expand significantly over the next several years. Companies are anticipated to make significant investments in R&D as the market changes to create cutting-edge TAVI devices that can adapt to patients' and physicians' changing demands.

The Solution to Your Market Challenges

Although there are many chances for expansion in the Transcatheter Aortic Valve Implantation (TAVI) industry, there are also a number of obstacles. The followings are some of the primary issues and possible solutions:

High Cost

TAVI operations can be pricey, which may prevent some patients from getting them.

Manufacturers may collaborate with payers to negotiate more advantageous reimbursement rates, or they could keep innovating and creating more affordable TAVI devices.

Limited Reimbursement in Some Markets

Even though many nations have favorable reimbursement rules, there are other markets where compensation is either very limited or non-existent.

The development of more affordable, cost-effective products that may be sold at lower price points or advocacy for improved reimbursement in these markets is two options for manufacturers.

Limited Availability of Experienced Physicians

TAVI procedures call for a high level of expertise and experience, which might restrict access to them in some regions.

Manufacturers investing in physician education initiatives and collaborating with medical societies and academic institutions to advance TAVI education and training are two potential solutions.

Risk Of Complications

Although TAVI operations are largely risk-free, problems like bleeding, stroke, or valve leakage can still occur.

Manufacturers may keep making investments in innovative device design and development to lower these hazards as well as in continuous patient monitoring and care to make sure they have the assistance they need.

Competition From Traditional Open-Heart Surgery

Even though TAVI treatments are becoming more and more common, open-heart surgery remains a threat.

To illustrate the advantages of TAVI treatments and broaden the pool of patients who are eligible for these operations, manufacturers might continue to make investments in research and development.

Opportunities in the Market

Expanding Indications

Although aortic stenosis is the primary condition that TAVI treatments are intended to treat, there is rising interest in using these procedures to address additional conditions such as aortic regurgitation and mitral regurgitation. The market is projected to expand as more information about the security and effectiveness of TAVI treatments for various purposes becomes available.

Emerging Markets

Many emerging economies still have a young TAVI market, which offers manufacturers great room for expansion. The market is projected to increase quickly in these areas as the healthcare infrastructure is improved and TAVI treatments become more widely known.

Advancements in Device Technology

As long as manufacturers keep spending money on R&D, there will be chances to create cutting-edge TAVI devices that give better results and lower dangers. Devices that can be utilized on patients with smaller or more intricate anatomies, as well as those that are more user-friendly and cost-effective, might fall under this category.

Aging Population

The frequency of aortic stenosis is anticipated to rise as the world's population ages, fueling demand for TAVI operations. In the ensuing years, this offers manufacturers a large possibility for expansion.

Patient Preference for Minimally Invasive Procedures
Minimally invasive treatments that provide quicker recovery periods and decreased risk of problems are becoming more popular with patients. These requirements are met by TAVI treatments, which are in great demand. The market is projected to expand as more patients learn about the advantages of TAVI operations.

Overall, the TAVI market offers tremendous growth potential for companies and investors that are prepared to spend money on R&D, expand into developing nations, and create cutting-edge TAVI devices that will suit the changing demands of both patients and doctors.

Direct Purchase of Transcatheter Aortic Valve Implantation (TAVI) Market Research Report at: https://www.delvens.com/checkout/transcatheter-aortic-valve-implantation-market-trends-forecast-till-2028

Contact Us:

UNIT NO. 2126, TOWER B,
21ST FLOOR ALPHATHUM
SECTOR 90 NOIDA 201305, IN
+44-20-8638-5055
SALES@DELVENS.COM
WEBSITE: https://delvens.com/

About Us:

Delvens is a strategic advisory and consulting company headquartered in New Delhi, India. The company holds expertise in providing syndicated research reports, customized research reports and consulting services. Delvens qualitative and quantitative data is highly utilized by each level from niche to major markets, serving more than 1K prominent companies by assuring to provide the information on country, regional and global business environment. We have a database for more than 45 industries in more than 115+ major countries globally.

Delvens database assists the clients by providing in-depth information in crucial business decisions. Delvens offers significant facts and figures across various industries namely Healthcare, IT & Telecom, Chemicals & Materials, Semiconductor & Electronics, Energy, Pharmaceutical, Consumer Goods & Services, Food & Beverages. Our company provides an exhaustive and comprehensive understanding of the business environment.

This release was published on openPR.